Best use of drug-eluting stents

September 02, 2008

When should they be avoided?

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use of drug-eluting stents necessitates extended treatment with dual antiplatelet therapy (aspirin plus thienopyridine) which may cause bleeding complications and interferes with or even precludes surgery in case this is needed.

In addition, from a socioeconomic standpoint, the increased cost associated with drug-eluting stents is a major issue.

Based on these considerations, drug-eluting stents should be avoided (a) when the expected benefit is low and (b) when the risk associated with extended dual antiplatelet therapy is high.

After placement of bare metal stents, the risk of restenosis varies considerably based on patient and lesion characteristics. Specifically, patients who do not suffer from diabetes have a substantially lower risk than diabetic patients. Strong lesion-specific predictors of a low risk of restenosis after bare metal stents include short lesion length and large vessel size. Thus, in non-diabetic patients with a short lesion in a large vessel, the risk of restenosis after placement of a bare metal stent is below 10 %. In these subsets, a substantial benefit from drug-eluting stents cannot be expected. These considerations are confirmed by data from randomized studies as well as from registries.

In patients with bleeding disorders, the risk of bleeding complications during dual antiplatelet therapy is particularly high. On the other hand, premature discontinuation of dual antiplatelet therapy for imminent or overt bleeding carries a substantial risk of stent thrombosis with potentially fatal outcome. A particularly difficult patient subset in this respect concerns those in need for anticoagulation, such as patients with atrial fibrillation at high risk for thromboembolic events or patients with prosthetic valve replacement. In these patients, interventional cardiologists are well advised to use a bare metal stent to keep the need for dual antiplatelet therapy as short as possible.

Drug-eluting stents should also be avoided in patients with planned surgical procedure and in those likely to undergo a surgery within the next year.

European Society of Cardiology

---

---

	Emerging Oral Antiplatelet Therapies for Acute Coronary Syndromes (Hospital Practice) by JTE Multimedia Emergency department physicians, along with hospitalists and interventional cardiologists, provide first-line care for patients experiencing symptoms potentially associated with acute coronary syndromes (ACS). Because these health care providers encounter and manage patients with varying degrees of risk, a clear understanding of the modes of action, benefits, and limitations of various therapeutic options is crucial for achieving optimal outcomes in the acute-care setting. Oral antiplatelet therapy has a major role in the acute care of patients with suspected ACS due to the critical role of platelets in the pathophysiology of disease. The current standard-of-care oral antiplatelet therapy for ACS is aspirin in combination with a P2Y12 adenosine diphosphate (ADP) receptor antagonist, most...
	The Burden of Peripheral Artery Disease and the Role of Antiplatelet Therapy (Postgradaute Medicine) by JTE Multimedia Along with coronary artery disease and cerebrovascular disease, peripheral artery disease (PAD) is primarily caused by atherosclerosis. In fact, PAD is a marker of advanced atherosclerotic disease, as evidenced from several studies that suggest approximately 60% of patients with PAD have polyvascular disease or manifestations of atherosclerosis in the coronary or cerebrovascular territories as well. However, despite a PAD prevalence that is > 15% in patients with cardiovascular risk factors aged 60 to 69 years and > 35% in patients aged 70 to 82 years, there is a lack of disease awareness on the part of both physicians and patients. This lack of awareness most likely contributes to the high cardiovascular risk associated with a diagnosis of PAD. For example, in the Reduction of...
	Antiplatelet Therapy In Ischemic Heart Disease (American Heart Association Clinical Series) by Stephen D. Wiviott (Author) * Draws from expertise of leaders in antiplatelet therapy * Easy-to-use layout enables rapid browsing * Edited by a member of the prestigious TIMI study group with long-standing experience in the field
	Antiplatelet Therapy in Clinical Practice by James J Ferguson III (Author), Nicolas AF Chronos (Author), Robert A. Harrington (Author) Antiplatelet agents have a powerful effect on subacute thrombosis after the placement of coronary stents. As adjunctive therapy to stent placement, they assist in the prevention of restenosis. Some clinicians are of the opinion that in a few years' time, antiplatelet agents will displace stenting and coronary angioplasty as the intervention of choice for coronary stenosis. The editors have assembled a great team of clinicians and researchers who are all experts with antiplatelet agents. This book is a practical and essential guide for all those working in interventional cardiology.
	Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology) by Arman T. Askari (Editor), A. Michael Lincoff (Editor) Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated...
	Handbook of Antiplatelet Therapy by Mare Cohen (Author) A wealth of information on antiplatelet therapy has erupted. Rapid advances have been made in antiplatelet therapy, and researchers are discovering the growing benefits of aspirin, the new IIb/IIIa receptor antagonists and the thienopyridines. The Handbook of Antiplatelet Therapy distills all that research into a usable, practical form. The editor and his distinguished team of contributors, all experts in the field, provide insights into their respective specialties, from a clear definition of the platelet to an examination of the roles of glycoprotein and aspirin. Both consultants and trainees alike will be enlightened by this guide.
	Platelets: Pathophysiology and antiplatelet drug therapy by Harvey J Weiss (Author)
	Perioperative Management of Patients Receiving Anticoagulant or Antiplatelet Therapy: A Clinician-Oriented and Practical Approach (DOI: 10.3810/hp.2011.10.921) (Hospital Practice) by JTE Multimedia The management of patients who are receiving warfarin, aspirin, clopidogrel, or combinations of these drugs and require their interruption because of an elective surgical or other invasive procedure is a common and sometimes challenging clinical problem. For the practicing clinician, there are 2 key issues for perioperative anticoagulant management: 1) having an approach to stratify patients according to their risk for thromboembolism when warfarin or antiplatelet drug therapy is interrupted, and also having an approach to stratify patients according to the risk of bleeding associated with the surgery or procedure; and 2) determining which patients may require bridging anticoagulation and, if required, how to administer bridging, typically with a low-molecular-weight heparin, before and...
	Dual antiplatelet therapy cuts ischemic events. (Clopidogrel Plus Aspirin for 1 Year).: An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2003. The length of the article is 727 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Dual antiplatelet therapy cuts ischemic events. (Clopidogrel Plus Aspirin for 1 Year). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 1 Page: 45(1) Distributed by Thomson...
	Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large ... An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2005. The length of the article is 1296 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Combo first to improve MI mortality in 12 years: dual antiplatelet therapy--aspirin plus a short course of clopidoxrel--shines in two large studies.(Cardiovascular medicine)(Myocardial Infarction) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 15, 2005 Publisher: International Medical News Group Volume: 35 Issue: 8 ...